Tests proton radiation before surgery for soft tissue sarcoma of the limbs and trunk
Tests proton radiation given before surgery in adults with soft tissue sarcoma.
Plain-language title generated from the registry record
Registry title: Pre-operative Hypofractionated Proton Therapy
Key facts
- Where
- Washington D.C., United StatesSee the site
Where in United States
- Sibley Memorial HospitalWashington D.C., United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Trial code
- NCT05917301
- Record updated
- 17 April 2026
- Original description
This study is being done to examine whether proton therapy for certain kinds of sarcomas (extremity and trunk soft tissue) is safe and effective. As part of the study, patients will have five fractions of proton therapy before the participants have surgery for the sarcoma. The study will measure wound complications and functional outcomes / quality of life after the procedures.Read full original descriptionShow less
PROspective Phase II Trial of Pre-operative Hypofractionated protoN Therapy for Extremity and Truncal Soft Tissue sarcOma
This study is being done to examine whether proton therapy for certain kinds of sarcomas (extremity and trunk soft tissue) is safe and effective. As part of the study, patients will have five fractions of proton therapy before the participants have surgery for the sarcoma. The study will measure wound complications and functional outcomes / quality of life after the procedures.
Patients will be asked to complete questionnaires about the treatment and quality of life from the time of enrollment until about two years after surgery. Otherwise, the participants will have standard of care follow ups with the treatment team.
Inclusion: Adult patients (≥18 years of age); Patients with primary or locally recurrent extremity or truncal soft tissue sarcoma; WHO/ECOG status ≤2.
Exclusion: History of prior local radiation therapy; Patients planned for systemic therapy including chemotherapy, targeted agents, and immunotherapy; Co-existing malignancy or treated malignancy in the last 2 years expected to limit life expectancy; does not include completely resected cutaneous basal cell carcinoma, squamous cell carcinoma, in situ breast or cervical malignancies, or other pathologies at the discretion of the investigators; Inability to tolerate treatment position for duration of simulation or treatment; Tumor originating in retroperitoneal location; Confirmed pregnancy.